Nephros (NEPH) Stock Overview
A commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NEPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Next Phase of Energy Storage: How NeoVolta Is Tackling America’s Power Crunch
Battery storage is no longer a niche corner of clean tech. It’s emerging as the backbone of America’s energy future.
Nephros, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.89 |
| 52 Week High | US$5.98 |
| 52 Week Low | US$1.36 |
| Beta | 1.33 |
| 1 Month Change | 14.52% |
| 3 Month Change | 34.16% |
| 1 Year Change | 233.65% |
| 3 Year Change | 321.55% |
| 5 Year Change | -28.92% |
| Change since IPO | -99.54% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price Surge
Oct 01
At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?
Sep 13Recent updates
Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price Surge
Oct 01At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?
Sep 13It's Down 26% But Nephros, Inc. (NASDAQ:NEPH) Could Be Riskier Than It Looks
Aug 07Nephros, Inc.'s (NASDAQ:NEPH) 79% Jump Shows Its Popularity With Investors
Jun 16Should You Think About Buying Nephros, Inc. (NASDAQ:NEPH) Now?
May 14Investors Still Aren't Entirely Convinced By Nephros, Inc.'s (NASDAQ:NEPH) Revenues Despite 32% Price Jump
Apr 18It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)
Oct 03We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn
Jul 14Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates
May 13After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar
Dec 18At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?
Dec 14Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation
Sep 28US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results
Aug 13Shareholder Returns
| NEPH | US Machinery | US Market | |
|---|---|---|---|
| 7D | -9.4% | 3.6% | 1.7% |
| 1Y | 233.7% | 10.5% | 14.5% |
Return vs Industry: NEPH exceeded the US Machinery industry which returned 10.5% over the past year.
Return vs Market: NEPH exceeded the US Market which returned 14.5% over the past year.
Price Volatility
| NEPH volatility | |
|---|---|
| NEPH Average Weekly Movement | 14.3% |
| Machinery Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NEPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NEPH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 31 | Robert Banks | www.nephros.com |
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants.
Nephros, Inc. Fundamentals Summary
| NEPH fundamental statistics | |
|---|---|
| Market cap | US$56.50m |
| Earnings (TTM) | US$1.33m |
| Revenue (TTM) | US$16.68m |
Is NEPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEPH income statement (TTM) | |
|---|---|
| Revenue | US$16.68m |
| Cost of Revenue | US$6.11m |
| Gross Profit | US$10.57m |
| Other Expenses | US$9.25m |
| Earnings | US$1.33m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 63.37% |
| Net Profit Margin | 7.95% |
| Debt/Equity Ratio | 0% |
How did NEPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 00:20 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nephros, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Anthony Vendetti | Maxim Group |